Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19567209 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4573347 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6847934 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL696687 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL4573341 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL13109196 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL9454369 | 0.79 | CYP2A6 (0.49) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6875879 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6852387 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL6852241 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| EP-4271672-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| CN-110869373-B | Antibiotic resistance disruptors | 伦敦皇家学院 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022225941-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| CN-110869373-A | Antibiotic resistance disruptors | 伦敦皇家学院 | 2020-03-06 | — | — | CN | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2007083207-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | disclosed |
| EP-1740569-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005105781-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-10 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014945-A1 | N-((hetero)aryl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamides; useful treating AD or common cancers by blocking the activity of gamma-secretase and reducing/preventing the formation of amyloidogenic Abeta peptides and by blocking the Notch signaling pathways that can interfere with cancer pathogenesis. | BACE1, APP, BACE2 | SMN1; SMN2 2998/4885KDM4E 1793/4885ALDH1A1 3005/4885 |
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | SMN1; SMN2 3631/4885KDM4E 3599/4885ALDH1A1 481/4885 |
| US-20070129341-A1 | IMIDAZOLE DERIVATIVES USED AS TAFIA INHIBITORS | TFPI, TFPI2, SERPINC1 | SMN1; SMN2 4630/4885KDM4E 2782/4885ALDH1A1 1472/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | SMN1; SMN2 3653/4885KDM4E 2263/4885ALDH1A1 1564/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | SMN1; SMN2 4417/4885KDM4E 733/4885ALDH1A1 747/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | SMN1; SMN2 1394/4885KDM4E 574/4885ALDH1A1 617/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | SMN1; SMN2 3653/4885KDM4E 2263/4885ALDH1A1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.